Xeris Biopharma (XERS) Upgraded to Buy: Here's Why

Xeris Biopharma (XERS) has received a Zacks Rank #2 (Buy) upgrade, driven by an upward trend in its earnings estimates. This revision is a key indicator for institutional investors, as improving earnings outlooks often precede stock price appreciation. Specifically, while the Zacks Consensus Estimate for FY2025 EPS is -$0.05, estimates have increased 3.6% over the past three months, positioning XERS in the top 20% of Zacks-covered stocks and suggesting potential near-term upside.

Analysis

Xeris Biopharma (XERS) has been upgraded to a Zacks Rank #2 (Buy), a move predicated entirely on positive revisions to its earnings estimates. While the fiscal year 2025 consensus earnings per share forecast remains negative at -$0.05, this figure represents a 3.6% improvement over the past three months. According to the source, this upward trend in analyst estimates is a significant leading indicator for near-term stock performance, as institutional investors often adjust their valuation models based on such changes. The upgrade places XERS within the top 20% of the over 4,000 stocks covered by the Zacks system, suggesting its earnings outlook is improving more favorably than that of many of its peers.

Key Decisions for Investors

• The upgrade to a Zacks Rank #2, driven by positive earnings estimate revisions, provides a quantifiable bullish signal for investors considering near-term upside potential in XERS.
• Despite the positive revisions, the company's projected 2025 EPS remains negative at -$0.05, so investors should scrutinize future earnings reports for evidence of a clear trajectory toward profitability.
• Given that the investment thesis presented is based solely on earnings estimate trends, it is critical to monitor for any future downward revisions, as this would likely invalidate the basis for the current 'Buy' rating.